Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can corneal transplant patients ditch steroids after one year?

NCT ID NCT05716945

Disease control Sponsor: Maastricht University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new, gentler steroid eye drop plan after corneal transplant surgery. The goal is to prevent rejection while reducing side effects like high eye pressure. About 342 adults getting a DMEK transplant will be followed for two years to see if a milder steroid works as well and if patients can safely stop all drops after one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 342 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Patients aged 21 years or older registered on the NOTR as candidates for DMEK corneal transplantation Exclusion Criteria: * Inability to complete follow up or comply with study procedures * The participant is vulnerable * Previous corneal graft in the study eye * Known sensitivity or contraindication to the ingredients in the study medications * History of uveitis * History of any herpes simplex infection * Human Leukocyte Antigen (HLA) typed allograft * Pregnancy (current and planned) or lactation * Use of other local or systemic immunosuppressive drugs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fuchs' endothelial dystrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bullous keratopathy corneal disorder Fuchs' endothelial dystrophy ocular hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fuchs' endothelial dystrophy Intraocular pressure Pseudophakic bullous keratopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam Universitair Medisch Centrum

    RECRUITING

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Deventer Ziekenhuis

    RECRUITING

    Deventer, Overijssel, 7400 GC, Netherlands

  • Gelre Ziekenhuizen

    RECRUITING

    Apeldoorn, Gelderland, 7300 DS, Netherlands

  • Leiden Universitair Medisch Centrum

    RECRUITING

    Leiden, South Holland, 2333 ZA, Netherlands

  • Maastricht Universitair Medisch Centrum+

    RECRUITING

    Maastricht, Limburg, 6202 AZ, Netherlands

  • Radboud Universitair Medisch Centrum

    RECRUITING

    Nijmegen, Gelderland, 6500 HB, Netherlands

  • Universitair Medisch Centrum Groningen

    NOT_YET_RECRUITING

    Groningen, Provincie Groningen, 9700 RB, Netherlands

  • Universitair Medisch Centrum Utrecht

    NOT_YET_RECRUITING

    Utrecht, Utrecht, 3584 CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.